Management of chronic noncancer pain in depressed patients

Postgraduate Medicine

Volumn 123, Issue 5, 2011, Pages 143-154

  Barkin, Robert L ^a,b   Barkin, Stacy J ^c   Irving, Gordon A ^d   Gordon, Allan ^e  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c Private Practice Health Psychology and Chemical Dependency   (United States)

^d Swedish Headache Center   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Chronic noncancer pain; Depression; Nonsteroidal anti infl ammatory drugs; Opioids

Indexed keywords

ANTIDEPRESSANT AGENT; CAPSAICIN; DELTA OPIATE RECEPTOR AGONIST; DICLOFENAC; DULOXETINE; HERBACEOUS AGENT; KAPPA OPIATE RECEPTOR AGONIST; LIDOCAINE; MU OPIATE RECEPTOR AGONIST; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMORPHONE; PARACETAMOL; PLACEBO; RUBEFACIENT; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

BLEEDING; CHRONIC PAIN; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; DYSPHORIA; FIBROMYALGIA; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; LOW BACK PAIN; MAJOR DEPRESSION; NAUSEA; NEURALGIA; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT EDUCATION; PHYSIOTHERAPY; POLYPHARMACY; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

ACETAMINOPHEN; ANALGESICS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER; HUMANS; LIDOCAINE; PAIN; TRANSDERMAL PATCH;

EID: 80052721865     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.09.2470     Document Type: Review

References (129)

1. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med. 2008;70(8):890-897.
2. Castro M, Kraychete D, Daltro C, Lopes J, Menezes R, Oliveira I. Comorbid anxiety and depression disorders in patients with chronic pain. Arq Neuropsiquiatr. 2009;67(4):982-985.
3. Leo RJ, Pristach CA, Streltzer J. Incorporating pain management training into the psychiatry residency curriculum. Acad Psychiatry. 2003;27(1):1-11.
4. Sullivan MD, Edlund MJ, Steffick D, Unützer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005;119(1-3):95-103.
5. Shaw WS, Means-Christensen AJ, Slater MA, et al. Psychiatric disorders and risk of transition to chronicity in men with first onset low back pain. Pain Med. 2010;11(9):1391-1400.
6. Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain. 2004;107(1-2):54-60.
7. Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64(10):1180-1188.
8. Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009;121(4):91-102.
9. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4(2):4-25.
10. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372.
11. Maloney E, Degenhardt L, Darke S, Nelson EC. Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav. 2009;34(9):723-729.
12. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417-433.
13. Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J. 2001;77(913):703-707.
14. Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343-355.
15. Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9): e1113-e1188.
16. Kadian (morphine sulfate sustained release capsules) [package insert]. Piscataway, NJ: Alpharma; 2007.
17. Dilaudid-HP (hydromorphone hydrochloride) [package insert]. North Chicago, IL: Abbott Laboratories; 2008.
18. Duragesic (fentanyl transdermal system) [package insert]. Ortho-McNeil-Raritan, NJ: Janssen Pharmaceuticals, Inc; 2009.
19. OxyContin (oxycodone HCl controlled-release tablets) [package insert]. Purdue Stamford, CT: Pharma LP; 2010.
20. Opana ER (oxymorphone hydrochloride extended-release tablets) [package isnert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2010.
21. Barkin RL, Barkin SJ. Reexamining the elderly patient's presentation with depression. Prim Care Companion J Clin Psychiatry. 2008; 10(5):415-416.
22. Avasarala JR, Cross AH, Trinkaus K. Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis. Mult Scler. 2003;9(3):307-310.
23. Glombiewski JA, Hartwich-Tersek J, Rief W. Depression in chronic back pain patients: prediction of pain intensity and pain disability in cognitive-behavioral treatment. Psychosomatics. 2010;51(2): 130-136.
24. Hall AM, Kamper SJ, Maher CG, Latimer J, Ferreira ML, Nicholas MK. Symptoms of depression and stress mediate the effect of pain on disability. Pain. 2011;152(5):1044-1051.
25. Pincus T, Burton AK, Vogel S, Field AP. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine. 2002;27(5):E109-E120.
26. Ang DC, Bair MJ, Damush TM, Wu J, Tu W, Kroenke K. Predictors of pain outcomes in patients with chronic musculoskeletal pain co-morbid with depression: results from a randomized controlled trial. Pain Med. 2010;11(4):482-491.
27. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician. 2006;9(3):215-225.
28. Manchikanti L, Damron KS, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study. Pain Physician. 2004;7(4):431-437.
29. Manchikanti L, Pampati V, Damron KS, Beyer CD, Barnhill RC, Fellows B. Prevalence of prescription drug abuse and dependency in patients with chronic pain in western Kentucky. J Ky Med Assoc. 2003;101(11):511-517.
30. Kirsh KL, Jass C, Bennett DS, Hagen JE, Passik SD. Initial development of a survey tool to detect issues of chemical coping in chronic pain patients. Palliat Support Care. 2007;5(3):219-226.
31. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307-315.
32. Ilgen MA, Zivin K, McCammon RJ, Valenstein M. Pain and suicidal thoughts, plans and attempts in the United States. Gen Hosp Psychiatry. 2008;30(6):521-527.
33. Neufeld E, O'Rourke N. Impulsivity and hopelessness as predictors of suicide-related ideation among older adults. Can J Psychiatry. 2009;54(10):684-692.
34. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
35. Camidge DR, Wood RJ, Bateman DN. The epidemiology of selfpoisoning in the UK. Br J Clin Pharmacol. 2003;56(6):613-619.
36. Berndt S, Maier C, Schütz HW. Polymedication and medication compliance in patients with chronic non-malignant pain. Pain. 1993;52(3):331-339.
37. Parsells Kelly J, Cook SF, et al. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
38. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part I: outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1):5-15.
39. Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2): 155-162.
40. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph R, Summers KH. Exposure to potential CYP450 pharmacokinetic drugdrug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract. 2011;11(4):325-336.
41. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
42. Chou R, Qaseem A, Snow V, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491.
43. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
44. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
45. de Miquel CA, Campayo JG, Flórez MT, et al. Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr. 2010;38(2):108-120.
46. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Accessed June 30, 2011.
47. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43.
48. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
49. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011;11(1):33-41.
50. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009;146(3):253-260.
51. Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain. J Pain. 2009;10(2):208-213.
52. Sullivan M, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain Med. 2009;10(5):806-812.
53. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3): 377-388.
54. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4): 476-499.
55. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 suppl):S3-S14.
56. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43(4): 342-349.
57. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87-93.
58. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272(23):1845-1850.
59. Associated Press. Muscle-pain reliever is blamed for Staten Island runner's death. New York Times. June 10, 2007.
60. Chan TY. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol. 1996;15(9):747-750.
61. Chan TY. The risk of severe salicylate poisoning following the ingestion of topical medicaments or aspirin. Postgrad Med J. 1996;72(844):109-112.
62. Pec J, Strmenova M, Palencarova E, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis. 1992;50(4):307-309.
63. Kuhn MA. Herbal remedies: drug-herb interactions. Crit Care Nurse. 2002;22(2):22-28, 30, 32; quiz 34-35.
64. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40.
65. Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010;27(10):775-789.
66. Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs. 2010;50:50-61.
67. Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(9):1991-1999.
68. Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed. 2010;38(2):19-28.
69. Barthel HR, Haselwood D, Longley S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203-212.
70. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-245.
71. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002-2012.
72. Zacher J, Burger KF, Farber L, Gräve M, Abberger H, Bertsch K. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Aktuelle Rheumatologie. 2001;26:7-14.
73. Baraf HS, Gold MS, Petruschke RA, Wieman MS. The tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. J Am Med Dir Assoc. In press.
74. Barkin RL. Nonopioid analgesics for osteoarthritis: availability of topical NSAIDs. J Pain Palliat Care Pharmacother. 2010;24(2): 180-181.
75. Zacher J, Burger KF, Farber L, Grave M, Abberger H, Bertsch K. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Postgrad Med. In press.
76. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology. 2002;58(4):554-563.
77. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(suppl 2):S21-S28.
78. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in postherpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663-1676.
79. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231-241.
80. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39-44.
81. Fishbain DA, Lewis JE, Cole B, Cutler B, Rosomoff HL, Rosomoff RS. Lidocaine 5% patch: an open-label naturalistic chronic pain treatment trial and prediction of response. Pain Med. 2006;7(2):135-142.
82. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin. 2004;20(suppl 2):S5-S12.
83. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4(4): 321-330.
84. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914-918.
85. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1-2):151-158.
86. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16(3):205-208.
87. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005;6(5):379-384.
88. Fleming JA, O'Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag. 2009;14(5): 381-388.
89. Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91(5):1343-1350.
90. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36(2):236-240.
91. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533-538.
92. Berrocoso E, Sanchez-Blazquez P, Garzón J, Mico JA. Opiates as antidepressants. Curr Pharm Des. 2009;15(14):1612-1622.
93. Jutkiewicz EM. The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv. 2006;6(3):162-169.
94. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008;98(3):191-202.
95. Schoedel KA, McMorn S, Zerbe K, Chakraborty B, Potts SL, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone. J Opioid Manag. 2010;13(6)561-573.
96. Brown RM, Lawrence AJ. Neurochemistry underlying relapse to opiate seeking behaviour. Neurochem Res. 2009;34(10):1876-1887.
97. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009;32(5):269-276.
98. Zahm DS. Pharmacotherapeutic approach to the treatment of addiction: persistent challenges. Mo Med. 2010;107(4):276-280.
99. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15(3):184-191.
100. American Academy of Pain Medicine and American Pain Society. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6-8.
101. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11(2 suppl):S155-S180.
102. Manchikanti L, Singh V, Damron KS, Beyer CD, Pampati V. Screening for controlled substance abuse in interventional pain management settings: evaluation of an assessment tool. Pain Physician. 2003;6(4):425-433.
103. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
104. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
105. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589-1594.
106. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199-1208.
107. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49-57.
108. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999;156(12):2017.
109. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.
110. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87(5-6):274-285.
111. Ultram ER (tramadol hydrochloride) [package insert]. Raritan, NJ: Ortho-McNeil; 2008.
112. ®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008.
113. Butrans Transdermal System (buprenorphine) [package insert]. Stamford, CT: Purdue Pharma LP; 2010.
114. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469-2475.
115. Hydrocodone bitartate and acetaminophen tablets [package insert]. Corona, CA: Watson Pharma; 2006.
116. Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008;24(1):297-305.
117. Fiske WD, Jobes J, Xiang Q, Chang S, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets. Ann Pharmacother. In press.
118. Johnson F, Wagner G, Sun S, Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain. 2008;9(4):330-336.
119. Barkin RL, Shirazi D, Kinzler E. Effect of ethanol on the release of morphine sulfate from Oramorph SR tablets. Am J Ther. 2009;16(6): 482-486.
120. Traynor MJ, Brown MB, Pannala A, Beck P, Martin GP. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm. 2008;34(8):885-889.
121. Clark MR, Treisman GJ. Optimizing treatment with opioids and beyond. Adv Psychosom Med. 2011;30:92-112.
122. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.
123. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144-156.
124. Webster LR, Webster RM. Predicting aberrant behaviors in opioidtreated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
125. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9(1):57-60.
126. Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. 4th ed: California Academy of Family Physicians; 2010.
127. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
128. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Dis Mon. 2011;57(5):248-285.
129. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/table.htm. Accessed June 16, 2011.